The research purpose is to evaluate the efficacy and safety of QS-M needle-free injector as a drug carrier in the control of blood glucose in patients with type 2 diabetes mellitus by non-inferiority study，using needle-insulin pen as the comparison. This is a prospective, multicenter, randomized, open and parallel grouping study. QS-M needle-free injector produced by Beijing QS medical technology co., Ltd.is used as the insulin carrier in the experimental group. While needle-insulin pen is used as the insulin carrier in the control group. In this study, we investigated whether the changes of glycosylated hemoglobin (HbAlc) at the 16th week in the experimental group respected to the baseline is non-inferiority compared with that in control group. A total of 420 cases were included in this study. The experimental group and the control group were assigned by 1:1 ratio.